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conceptual understanding ofthe material. Answers and references for further reading
are provided.
Clinical Epidemiology is an interesting presentation of a field that is generally not
described in clinically applicable terms; however, the author's discussion of several
epidemiologic methods and principles is incomplete. For example, limitations in the
use of the kappa coefficient as a method ofquantifying inter-observer agreement are
not adequately addressed. In addition, confounding receives too little attention
considering its importance in conducting and evaluating research. These shortcomings
are important but do not diminish the relevance of understanding epidemiologic
techniques in a clinical setting. Clinical investigators will find the text to be a valuable
supplemental resource for conducting research, while other readers will discover it to
be an insightful tool for evaluating clinical research.
The author achieves a rare balance with Clinical Epidemiology: The Architecture
of Clinical Research. Quantitative methods of analysis are complemented with
discussions of theoretical strategies of research, and the text is framed within a
well-developed historical context of public health and clinical epidemiology. Dr.
Feinstein has written a textbook of clinical epidemiology that is rarely traditional,
sometimes controversial, and always interesting.
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IMMUNITY TO CANCER. Edited by Arnold E. Reif and Malcolm S. Mitchell. Orlando,
FL, Academic Press, Inc., Publishers, 1985. 659 pp. $43.00.
Immunity to Cancer is a volume containing 45 papers and six brief reports,
presented at a conference of the same title, held in September 1984 at Williamsburg,
Virginia. Written by a representative group of leaders in this field, the papers are
organized under five headings: Identification and Characterization of Tumor Anti-
gens, Immune Responses to Tumor Antigens, Regulation of the Immune Response to
Tumor Cells, Immunotherapy and Biomodulators, and Immunoprophylaxis.
In the first section, "Tumor Antigen Characterization," an opening chapter by
editor Reif detailing requirements for success in immunotherapy is followed by a
discussion on the origin and nature of tumor antigens. Specific tumor antigens in
human melanoma, lymphoma, Simian virus 40 transformed cells, and leukemia are
discussed in the eight papers that follow, and the means of their characterization is
described.
"Immune Responses to Tumor Antigens" is the topic ofthe second section, with the
emphasis on effector mechanisms, including NK, macrophage, humoral, and T-cell
responses to challenge by tumor antigens. The regulation of these responses is the
subject of the third section, where cellular interaction and the role of lymphokines in
tumor rejection is reviewed.
The fascinating field of biological response modifiers (BRMs) is the subject of the
fourth section. Both reviews of current developments and original research are
presented, as thymosins, extracted tumor-specific transplantation antigens, and inter-
leukin 2 are discussed as possible inducers ofthe immune response against neoplasia.80 BOOK REVIEWS
The final section of the book, covering immunotherapy and immunoprophylaxis,
contains papers on antibody-drug conjugates, vaccination against virally induced
tumors, and passive immunotherapy with monoclonal antibodies to differentiation
antigens. A succinct conference summary by editor Mitchell closes the volume,
outlining well the material presented.
Immunity to Cancer is a comprehensive coverage of the first conference in nine
years to address the range ofsubjects included in tumor immunology and immunother-
apy. The authors are experienced in the field, and this volume offers an excellent
reference for many ofthe recent developments in the subject.
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